A Phase 1/2 interventional study of Atezolizumab and DEC-205/NY-ESO-1 Fusion Protein CDX-1401 in Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma and Platinum-Resistant Primary Peritoneal Carcinoma, sponsored by National Cancer Institute (NCI). Terminated at 17 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by National Cancer Institute (NCI) · Phase 1/2, Interventional, and Treatment
How we know · 9 judgments
The study was terminated due to a shortage of the drug supply.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Fallopian Tube Neoplasms by National Cancer Institute (NCI) — 1 open to participants now, 20 under way, 5 of them phase 3. Fallopian Tube Neoplasms · National Cancer Institute (NCI).
Among the 82 studies in Fallopian Tube Neoplasms by National Cancer Institute (NCI), this one is the 70th largest by enrollment of the 73 interventional ones that give a count, is one of 5 that started in 2017, is one of 5 in phase 1/2, and was the 74th registered.
835 studies on the registry are indexed under Fallopian Tube Neoplasms; 128 are open to participants now.
Browse Fallopian Tube Neoplasms studies →1 of the 82 studies in Fallopian Tube Neoplasms by National Cancer Institute (NCI) is open now, in 2 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States, Puerto Rico
By country, each count listing its studies:
Of the 104 Fallopian Tube Neoplasms studies recruiting now, 85 (82%) set no upper age limit and 10 (10%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 46 · Phase 3 8
First in 1998; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 50 across 684 interventional studies indexed under Fallopian Tube Neoplasms.
Median enrollment 50 across the 73 interventional studies, 119 across the 3 observational. Of the 61 that completed or were terminated, 34 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
2 of the studies in Fallopian Tube Neoplasms by National Cancer Institute (NCI) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05691504National Cancer Institute (NCI)Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers | 2027-02-01 |
| NCT04314401National Cancer Institute (NCI)National Cancer Institute "Cancer Moonshot Biobank" | 2027-04-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 82 studies in Fallopian Tube Neoplasms by National Cancer Institute (NCI), from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized phase I/IIb trial studies side effects and best dose of atezolizumab when given together with guadecitabine and CDX-1401 vaccine and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CDX-1401 vaccine may enhance the expression of the genes encoding tumor antigens on the surface of tumor cells and enhance the activity of tumor-killing T cells against those tumor cells. Vaccines made from monoclonal antibodies combined with tumor cells may help the body build an effective immune response to kill tumor cells. Giving atezolizumab, guadecitabine, and CDX-1401 vaccine may work better than CDX-1401 alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
PRIMARY OBJECTIVES:
I. To determine the safety of fixed doses of atezolizumab (MPDL3280A) in combination with guadecitabine (SGI-110). (Phase I) II. To evaluate toxicity of the combination as defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. (Phase I) III. To study if SGI-110 improves the benefit of atezolizumab and then if the further addition of the DEC-205/NY-ESO-1 fusion protein CDX-1401 (CDX-1401)/poly ICLC adds further clinical benefit by analyzing progression free survival (PFS), using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. (Phase IIb)
SECONDARY OBJECTIVES:
I. To observe and record anti-tumor activity. (Phase I) II. To determine overall survival (OS), objective response rate (complete and partial responses), clinical benefit rate (response + stable disease), CA-125 reduction (percentage of patients with CA-125 reduction by >= 50%), and duration of response. (Phase IIb) III. To assess the impact of the combination of atezolizumab, SGI-110, and CDX-1401 on anti-tumor immune responses. (Phase IIb) IV. To assess the impact of SGI-110 on NY-ESO-1 expression in tumor tissue. (Phase IIb) V. To assess toxicities associated with the combination cohorts (2 and 3), as there is little human experience with these combinations. (Phase IIb)
EXPLORATORY/TRANSLATIONAL OBJECTIVES:
I. To determine the effectiveness of SGI-110 on enhancing vaccine efficacy by assessing NY ESO 1 specific cellular and humoral immunity.
Ia. Peripheral blood NY ESO 1 specific CD8+ and CD4+ T cells. Ib. Peripheral blood NY ESO 1 specific antibodies. Ic. Peripheral blood unrelated CTA specific antibodies (antigen spreading). Id. Peripheral blood frequency of CD4+CD25+FOXP3+ regulatory T cells. Ie. Examine potential differential effect of NY-ESO-1 expression on PFS. II. To assess the impact on PDL1 expression in tumor tissue. III. Evaluation of therapeutic efficacy on immune cell phenotype. IV. Deoxyribonucleic acid (DNA) methylation and DNA methylome: in pre- and on-treatment peripheral blood, serum (circulating DNA), and tumor biopsies.
V. Pre-and on-treatment density and location of tumor infiltrating CD3+ and CD8+ T cells.
VI. Evaluate the pre- and post-treatment mutational and neo-antigen load and therapeutic efficacy.
VII. Pre- and post-treatment T cell receptor (TCR) repertoire to study the effect of TCR V beta diversity due to combination of PDL1 blockade, epigenetic modification, and vaccination on therapeutic efficacy.
VIII. Gut microbiota at baseline and one on-treatment sample at C4D1 (cycle 4, day 1) or at progression, whichever is earlier to evaluate the role of microbiota on the therapeutic efficacy of the proposed combination therapy.
OUTLINE: This is a phase I, dose-escalation study of guadecitabine followed by a phase IIb study. Patients are randomized to 1 of 3 cohorts.
COHORT I: Patients receive atezolizumab intravenously (IV) over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
COHORT II: Patients receive guadecitabine subcutaneously (SC) on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on days 8 and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
COHORT III: Patients receive guadecitabine and atezolizumab as in Cohort II. Patients also receive CDX-1401 vaccine IV on day 15 and poly ICLC SC on days 15-16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 2 months for up to 1 year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prior treatment with , or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Patients who have received prior treatment with anti-CTLA-4 may be enrolled, provided the following requirements are met:
Treatment with systemic medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1
Known liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease
History or risk of disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis
Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:
Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab
Patients positive for (HIV) are NOT excluded from this study, but HIV-positive patients must have:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
Drug: Atezolizumab · Other: Laboratory Biomarker Analysis
Patients receive guadecitabine SC on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes on days 8 and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
Drug: Atezolizumab · Drug: Guadecitabine · Other: Laboratory Biomarker Analysis
Patients receive guadecitabine and atezolizumab as in Cohort II. Patients also receive CDX-1401 vaccine IV on day 15 and poly ICLC SC on days 15-16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Drug: Atezolizumab · Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401 · Drug: Guadecitabine · Other: Laboratory Biomarker Analysis · Drug: Poly ICLC
Given IV
Also known as: MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq
Drug page: Rasdegafusp alfaStudies of Rasdegafusp alfaRasdegafusp alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Given SC
Also known as: CDX-1401
Given SC
Also known as: DNMT inhibitor SGI-110, S110, SGI 110, SGI-110, SGI110
Correlative studies
Given SC
Also known as: Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid
Incidence of Adverse Events (AE) (Phase I)
The number of patients that had a maximum adverse event \>= grade 4 ( Common Terminology Criteria for Adverse Events version 5.0)
Time frame: Up to 30 days after last dose
Progression Free Survival (PFS) (Phase IIb)
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Progression free survival (PFS) (Phase IIb) is not evaluable.
Time frame: Till primary study completion date, approximately 3 years
Anti-tumor Activity (Phase I) II
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. Anti-tumor activity was not collected.
Time frame: Up to 1 year
Overall Survival (OS) (Phase IIb)
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Overall survival (OS) (Phase IIb) is not evaluable.
Time frame: Till primary study completion date, approximately 3 years
Objective Response Rate (Phase IIb)
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. TheObjective response rate (Phase IIb) is not evaluable.
Time frame: After 30 days after the last dose of study drug
Clinical Benefit Rate (Phase IIb)
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Clinical benefit rate (Phase IIb) is not evaluable.
Time frame: After 30 days after the last dose of study drug
CA-125 Reduction (Phase IIb)
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The CA-125 reduction (Phase IIb) is not evaluable.
Time frame: CA-125 were followed up from the start date of intervention till 39 months.
Duration of Response (Phase IIb)
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Duration of response (Phase IIb) is not evaluable.
Time frame: After 30 days after the last dose of study drug
Anti-tumor Immune Responses
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Anti-tumor immune responses (Phase IIb) is not evaluable.
Time frame: Anti-tumor immune responses were followed up from the start date of intervention till 39 months.
Epigenetic Modification of Immune Gene Signatures, NY-ESO-1, Other CTAs, and PDL 1 in the Tumor Microenvironment
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Epigenetic modification of immune gene signatures, NY-ESO-1, other CTAs, and PDL 1 in the tumor microenvironment (Phase IIb) is not evaluable.
Time frame: Epigenetic modification of immune gene signatures, NY-ESO-1, other CTAs, and PDL 1 in the tumor microenvironment were followed up from the start date of intervention till 39 months.
Incidence of Adverse Events With the Combination Cohorts (2 and 3) (Phase IIb)
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Incidence of adverse events with the combination cohorts (2 and 3) (Phase IIb) is not evaluable.
Time frame: Incidence of adverse events with the combination cohorts (2 and 3) (Phase IIb) were followed up from the start date of intervention till 39 months.
The study was terminated in 2020 early due to the cellular product being discontinued. Hence only 9 (instead of 12 as proposed in the protocol) patients were accrued by the termination time.
| Milestone | Cohort II (Guadecitabine, Atezolizumab) | Cohort I (Atezolizumab) | Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine) | Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose Guadecitabine |
|---|---|---|---|---|
| Started | 3 | 0 | 0 | 6 |
| Completed | 3 | 0 | 0 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
The number of patients that had a maximum adverse event \>= grade 4 ( Common Terminology Criteria for Adverse Events version 5.0)
| Participants | Cohort I (Atezolizumab) | Cohort II (Guadecitabine, Atezolizumab) | Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine) | Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose Guadecitabine |
|---|---|---|---|---|
| Incidence of Adverse Events (AE) (Phase I) | 0 | 0 | 0 | 6 |
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Progression free survival (PFS) (Phase IIb) is not evaluable.
No measurements were reported for this outcome.
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. Anti-tumor activity was not collected.
No measurements were reported for this outcome.
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Overall survival (OS) (Phase IIb) is not evaluable.
No measurements were reported for this outcome.
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. TheObjective response rate (Phase IIb) is not evaluable.
No measurements were reported for this outcome.
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Clinical benefit rate (Phase IIb) is not evaluable.
No measurements were reported for this outcome.
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The CA-125 reduction (Phase IIb) is not evaluable.
No measurements were reported for this outcome.
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Duration of response (Phase IIb) is not evaluable.
No measurements were reported for this outcome.
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Anti-tumor immune responses (Phase IIb) is not evaluable.
No measurements were reported for this outcome.
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Epigenetic modification of immune gene signatures, NY-ESO-1, other CTAs, and PDL 1 in the tumor microenvironment (Phase IIb) is not evaluable.
No measurements were reported for this outcome.
The study was terminated in 2020 early due to the cellular product being discontinued. The study did not proceed to the Phase II, so there were no participants in the Phase II part. The Incidence of adverse events with the combination cohorts (2 and 3) (Phase IIb) is not evaluable.
No measurements were reported for this outcome.
Collected over Routine AE's will be reported from the start date of intervention, at all visits except for week six till last follow up up to 36 months after treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort I (Atezolizumab) | — | — | — |
| Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine) | — | — | — |
| Cohort II (Guadecitabine, Atezolizumab) | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose Guadecitabine | 4/6 (66.7%) | 5/6 (83.3%) | 6/6 (100%) |
| Event | Cohort I (Atezolizumab) | Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine) | Cohort II (Guadecitabine, Atezolizumab) | Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose Guadecitabine |
|---|---|---|---|---|
| FeverGeneral disorders | — | — | 2/3 | 0/6 |
| Abdominal distensionGastrointestinal disorders | — | — | 1/3 | 0/6 |
| Abdominal painGastrointestinal disorders | — | — | 1/3 | 0/6 |
| BloatingGastrointestinal disorders | — | — | 1/3 | 0/6 |
| Small intestinal obstructionGastrointestinal disorders | — | — | 1/3 | 0/6 |
| small bowel obstructionGastrointestinal disorders | — | — | 1/3 | 0/6 |
| disease progressionGeneral disorders | — | — | 0/3 | 2/6 |
| Tooth infectionInfections and infestations | — | — | 1/3 | 0/6 |
| hydronephrosisRenal and urinary disorders | — | — | 1/3 | 0/6 |
| AnemiaBlood and lymphatic system disorders | — | — | 0/3 | 1/6 |
| Event | Cohort I (Atezolizumab) | Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine) | Cohort II (Guadecitabine, Atezolizumab) | Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose Guadecitabine |
|---|---|---|---|---|
| Alkaline phosphatase increasedInvestigations | — | — | 3/3 | 1/6 |
| AnemiaBlood and lymphatic system disorders | — | — | 2/3 | 2/6 |
| FatigueGeneral disorders | — | — | 2/3 | 3/6 |
| HyponatremiaMetabolism and nutrition disorders | — | — | 1/3 | 4/6 |
| ProteinuriaRenal and urinary disorders | — | — | 2/3 | 0/6 |
| ConstipationGastrointestinal disorders | — | — | 1/3 | 3/6 |
| Aspartate aminotransferase increasedInvestigations | — | — | 1/3 | 3/6 |
| Neutrophil count decreasedInvestigations | — | — | 1/3 | 3/6 |
| EosinophiliaBlood and lymphatic system disorders | — | — | 1/3 | 0/6 |
| Increased LDHBlood and lymphatic system disorders | — | — | 1/3 | 0/6 |
The study was terminated in 2020 early due to the cellular product being discontinued.
| Age, Categorical(Participants) | Cohort I (Atezolizumab) | Cohort II (Guadecitabine, Atezolizumab) | Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine) | Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose Guadecitabine | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 3 | 0 | 2 | 5 |
| >=65 years | 0 | 0 | 0 | 4 | 4 |
| Age, Continuous(years) | Cohort I (Atezolizumab) | Cohort II (Guadecitabine, Atezolizumab) | Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine) | Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose Guadecitabine | Total |
|---|---|---|---|---|---|
| Median | — | 47 (45 to 57) | — | 69.5 (54 to 76) | 57 (45 to 76) |
| Sex: Female, Male(Participants) | Cohort I (Atezolizumab) | Cohort II (Guadecitabine, Atezolizumab) | Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine) | Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose Guadecitabine | Total |
|---|---|---|---|---|---|
| Female | 0 | 3 | 0 | 6 | 9 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort I (Atezolizumab) | Cohort II (Guadecitabine, Atezolizumab) | Cohort III (Guadecitabine, Atezolizumab, CDX-1401 Vaccine) | Cohort II (Guadecitabine, Atezolizumab) - Escalated Dose Guadecitabine | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 2 | 0 | 6 | 8 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in Nov 2020, 36 months.
Results were first posted in Oct 2026, 5 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
The study was terminated due to a shortage of the drug supply.
The study was terminated due to a shortage of the drug supply.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Institute (NCI) →